Otonomy, Inc. (OTIC)
| Market Cap | 112.80M |
| Revenue (ttm) | 178,000 |
| Net Income (ttm) | -48.25M |
| Shares Out | 56.68M |
| EPS (ttm) | -0.81 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 2.03 |
| Previous Close | 2.03 |
| Day's Range | 1.98 - 2.07 |
| 52-Week Range | 1.14 - 5.73 |
| Beta | 1.76 |
| Analysts | Strong Buy |
| Price Target | 6.30 (+216.6%) |
| Earnings Date | Nov 10, 2021 |
About OTIC
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone that has completed Phase III clinical trial for the treatment of Ménière's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed Phase I/II clinica...
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for Otonomy stock is "Strong Buy." The 12-month stock price forecast is 6.30, which is an increase of 216.58% from the latest price.
News
Otonomy Reports Corporate and Product Pipeline Update
Multiple clinical trial readouts for OTO-313 in tinnitus and OTO-413 in hearing loss expected during 2022
Otonomy to Participate in the H.C. Wainwright BioConnect Conference
SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its partic...
Otonomy to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its partic...
Otonomy (OTIC) Reports Q3 Loss, Lags Revenue Estimates
Otonomy (OTIC) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Otonomy Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Conference call and webcast today at 4:30 p.m. ET
Otonomy to Report Third Quarter 2021 Financial Results and Provide Corporate Update
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will re...
Otonomy (OTIC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Otonomy (OTIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Otonomy Announces Publication of Phase 1/2 Trial Results Showing Tinnitus Improvement in Patients Receiving OTO-313
SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the public...
Otonomy Announces Presentation of OTO-413 Clinical Results at AAO-HNS Annual Meeting
SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the prese...
Otonomy to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that mana...
Otonomy Appoints Jill Broadfoot to Board of Directors
SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the appoin...
Otonomy (OTIC) Reports Q2 Loss, Lags Revenue Estimates
Otonomy (OTIC) delivered earnings and revenue surprises of -11.76% and -46.15%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Otonomy Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Conference call and webcast today at 4:30 p.m. ET
Otonomy to Report Second Quarter 2021 Financial Results and Provide Corporate Update
SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will re...
Will Otonomy (OTIC) Report Negative Q2 Earnings? What You Should Know
Otonomy (OTIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Otonomy Initiates Expansion of Phase 1/2 Clinical Trial for OTO-413 in Hearing Loss
SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initia...
Otonomy's OTO-825 Gene Therapy Can Restore Meaningful Hearing Function, Animal Study Shows
Otonomy Inc (NASDAQ: OTIC) may have hit a snag with the development of its lead ear disorder candidate Otividex. Still, the company is trumpeting an early win for a gene therapy designed to treat congen...
Otonomy and AGTC Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting
OTO-825 administration rescues hearing and cochlear damage in two preclinical models of congenital hearing loss caused by GJB2 deficiency OTO-825 administration rescues hearing and cochlear damage in tw...
Otonomy Reports First Quarter 2021 Financial Results and Provides Corporate Update
Conference call and webcast today at 4:30 p.m. ET
Otonomy to Report First Quarter 2021 Financial Results and Provide Corporate Update
SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will rep...
Otonomy and AGTC to Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting
AAV-mediated gene therapy rescues hearing and cochlear damage in two preclinical models of congenital hearing loss caused by GJB2 deficiency AAV-mediated gene therapy rescues hearing and cochlear damage...
Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO, April 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the closi...
Otonomy Announces Pricing of $30.1 Million Public Offering
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the prici...
Otonomy Announces Proposed Public Offering
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that it h...
Otonomy to Present at the Needham Virtual Healthcare Conference
SAN DIEGO, April 06, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its parti...